1,552 results on '"Helliwell, Philip"'
Search Results
2. 50 years of spondyloarthritis: a look back and a look ahead
3. Patients’ perspectives on systemic sclerosis-related Raynaud's phenomenon in the feet: A qualitative study from the OMERACT Foot and Ankle Working Group
4. Psoriatic Arthritis
5. Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies
6. Developing an Outcome Measures in Rheumatology (OMERACT) Core set of Outcome Measures for FOot and ankle disorders in RheumaTic and musculoskeletal diseases (COMFORT): core domain set study protocol
7. Living with foot and ankle disorders in rheumatic and musculoskeletal diseases: A systematic review of qualitative studies to inform the work of the OMERACT Foot and Ankle Working Group
8. Developing a core outcome set for foot and ankle disorders in rheumatic and musculoskeletal diseases: A scoping review and report from the OMERACT 2022 foot and ankle special interest group session
9. Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phase 3 Study
10. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021
11. Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis (COMPLETE-PsA): a double-blind, placebo-controlled, randomised, trial
12. Incidence of Psoriatic Arthritis in a Primary Care Psoriasis Population in the United Kingdom.
13. The Development and Validation of a Novel Training Infographic for the Physician Global Visual Analog Scale in Psoriatic Arthritis.
14. GRAPPA 2023: Major Projects, Key Advances, and Milestones.
15. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
16. Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
17. Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies
18. Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial
19. P006 A new digital front door for existing rheumatology patient queries
20. E072 The psoriatic arthritis disease activity score demonstrates excellent test-retest reliability in early, untreated psoriatic arthritis
21. Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies
22. Chemical Bioconjugation of Proteins in an Undergraduate Lab: One-Pot Oxidation and Derivatization of the N-Terminus
23. Pro and contra: is synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) a spondyloarthritis variant?
24. An Unusual Case of Widespread, Pruritic Metastatic Crohn’s
25. Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
26. How do patient-reported outcome measures affect treatment intensification and patient satisfaction in the management of psoriatic arthritis? A cross sectional study of 503 patients
27. Recent advances in the management of psoriatic arthritis: practical considerations
28. High prevalence of undiagnosed and undertreated psoriasis in a UK urban population: results from the observational COPPACA study.
29. Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis, Palmoplantar Pustulosis, and Neutrophilic Dermatoses: A GRAPPA 2023 Annual Meeting Update.
30. The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Celebrates Its 20th Anniversary.
31. Author Correction: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021
32. The Diagnosis and Treatment of Adult Patients with SAPHO Syndrome: Controversies Revealed in a Multidisciplinary International Survey of Physicians
33. Application of information theoretic feature selection and machine learning methods for the development of genetic risk prediction models
34. The BSR-PsA: study protocol for the British Society for Rheumatology psoriatic arthritis register
35. Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib
36. Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response—results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis
37. The comparative performance of three screening questionnaires for psoriatic arthritis in a primary care surveillance study.
38. High prevalence of radiographic erosions in early, untreated PsA: results from the SpARRO cohort.
39. An international multi-centre analysis of current prescribing practices and shared decision-making in psoriatic arthritis
40. Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients
41. Assessing Disease Activity in Psoriatic Arthritis: A Literature Review
42. Pathophysiology, assessment and treatment of psoriatic dactylitis
43. Screening and Referral Strategies for the Early Recognition of Psoriatic Arthritis Among Patients With Psoriasis: Results of a GRAPPA Survey
44. Initiating Evaluation of Composite Outcome Measures for Psoriatic Arthritis: 2022 Updates From the GRAPPA-OMERACT Working Group
45. GRAPPA Historical Perspective
46. The Natural History of Psoriatic Arthritis
47. La fatigue dans le rhumatisme psoriasique. Étude transversale portant sur 246 patients de 13 pays
48. Que signifie l’évaluation globale par le patient dans le rhumatisme psoriasique ? Une analyse de 223 patients issus de l’étude d’élaboration du Psoriatic Arthritis Impact of Disease (PsAID)
49. Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA)
50. Clinical trajectories of hand function impairment in systemic sclerosis: an unmet clinical need across disease subsets.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.